Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 7Active not recruiting 4Withdrawn 3Unknown 3Terminated 3Recruiting 3Suspended 1Not yet recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 3Dermatologic 1

Conditions

Lymphoma, Large B-Cell, Diffuse 19Sarcoma 15Burkitt Lymphoma 9Breast Neoplasms 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Neoplasm Metastasis 8Triple Negative Breast Neoplasms 7Lymphoma, T-Cell, Peripheral 7Lymphoma, Follicular 7Lymphoma, B-Cell 7Ovarian Neoplasms 6Lymphoma 6Hodgkin Disease 6Endometrial Neoplasms 5Osteosarcoma 4Neuroblastoma 4Lymphoma, Non-Hodgkin 4Liposarcoma 4Recurrence 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Peritoneal Neoplasms 3Neoplasms 3Leukemia, Biphenotypic, Acute 3Leiomyosarcoma 3Histiocytoma, Malignant Fibrous 3Hemangiosarcoma 3Colorectal Neoplasms 3Uterine Neoplasms 2Stomach Neoplasms 2Sarcoma, Synovial 2

Interventions

Cyclophosphamide 11venetoclax 10Dexamethasone 8Cytarabine 7Vincristine 5Azacitidine 4mogamulizumab 3fludarabine phosphate 3fludarabine 3daratumumab 3Specimen Handling 3Prednisone 3Methotrexate 3Doxorubicin 3Dasatinib 3Biopsy 3ruxolitinib 2prednylidene 2pegaspargase 2nelarabine 2deltacortene 2calaspargase pegol 2Rituximab 2Mercaptopurine 2Etoposide 2Decitabine 2Daunorubicin 2Calcium Dobesilate 2Bortezomib 2Asparaginase 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Precursor T-Cell Lymphoblastic Leukemia-Lymphoma × Doxorubicin × Clear all
NCT06738368 2026-05-12

Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia

University of Washington

Phase 2 Recruiting
30 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT05996185 2026-04-14

Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma

Yale University

Phase 2 Recruiting
22 enrolled
DermatologicLymphoidOther hematologic neoplasm

Recurrence, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT00501826 2026-01-07

Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

M.D. Anderson Cancer Center

Phase 2 Recruiting
160 enrolled
LymphoidOther hematologic neoplasm

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡